Site Selection in Europe: Germany, UK, Netherlands Rank High
Against the backdrop of recent statistics showing that applications to run clinical trials in Europe fell 25% between 2007-2011
Against the backdrop of recent statistics showing that applications to run clinical trials in Europe fell 25% between 2007-2011, the SAT-EU study group, an independent non-profit collaborative initiative, supported by the European Forum for Good Clinical Practice (EFGCP) and several other trade and not-for profit organizations, announced the results of a survey, Factors Influencing Clinical Trial Site Selection in Europe: The Survey of Attitudes towards Trial Sites in Europe. Published research based on that survey is now online in the British Medical Journal's BMJ Open.
Apparently, administrative burdens and unhelpful bureaucratic barriers are key deterrents to running clinical trials in Europe, according to the survey, while costs of running trials, as week as any governmental or financial incentives are considered to be of lower importance. “This study seems to indicate that fostering competitiveness of European clinical research may not require additional government spending/incentives. Rather, harmonization of approval processes, greater visibility of centers of excellence, and reduction of hidden indirect costs, may bring significantly more clinical trials to Europe,” commented Ingrid Klingmann, Chairman of the European Forum for Good Clinical Practice (EFGCP).
The research paper also found considerable variability in the perceived receptivity of countries to undertake clinical trials. Germany, the United Kingdom, and the Netherlands were consistently rated the best trial markets, which led authors to suggest a best practice audit of provisions governing clinical trials in these countries would be helpful.
Applied Clinical Trials supported the survey by providing outreach for the collaborative study group survey to our readership.
You can read the full release here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
